Boylston Properties Launches Property Management Arm Led by Robyn Duffy, New Director of Property Management
Duffy will lead Boylston Properties Management Company at the Growing Life Science Campus at Arsenal Yards
Thursday, May 19, 2022 – Boston, MA – Boylston Properties, a Boston-based developer of mixed-use properties, announced today that Robyn Duffy is joining as Director of Property Management, leading a new vertically-integrated property management arm of the growing real estate firm. The launch of Boylston Properties Management Company (BPMC) follows the development of 400,000 sf of state-of-the-art life science space at Arsenal Yards in Watertown, and enables the firm to stay as close as possible to the end-user experience.
Boylston Properties Management Company is being created to offer professional property management services with a commitment to proactiveness, efficiency, and a personalized, first-class tenant experience. Boylston Properties launched BPMC in its life science portfolio of 108,000 sf at 200 Arsenal Yards Blvd, which is fully occupied by three tenants, in addition to several retail properties in Boston and Needham that it will also serve. BPMC will be further built out ahead of November 2022, when seven additional life science tenants will move in to the remaining approximate 300,000 sf at the future 100 and 500 Forge life science properties at Arsenal Yards.
“If there’s one thing that our team is known for, it’s close, valued tenant relationships and strong industry partnerships,” said Bill McQuillan, Founding Principal of Boylston Properties. “We’re bringing property management in-house because we aim to deliver professional, white-glove service and work with best-in-class partners — from development, through construction, and now full circle to tenant relations and day-to-day management. Robyn has been our partner for 6 years, beginning at the LINX building in Watertown, and she is the perfect person to drive BPMC. She understands our values and appreciates what we aim to deliver at our properties day-in and day-out.”
Robyn Duffy joins Boylston Properties from Jones Lang LaSalle (JLL), where she has been a Group Manager since 2019, managing a portfolio of 800,000 square feet of lab, medical office, office and industrial space. As a Group Manager, Robyn was responsible for client relations, team training and growth, implementation of strategic plans for properties, and creating, managing, and reviewing annual budgets and financials. Prior to joining JLL, Robyn worked as the Senior Property Manager for Lincoln Property Company where she was responsible for the management and oversight of a mixed-use portfolio of 28 buildings which included retail, residential, and office on Newbury Street in Boston’s Back Bay.
Read the full press release
Boylston Properties and J.P. Morgan Complete Purchase of 615 Arsenal St. in Watertown for $96.25M
Boylston Properties, a Boston-based developer of mixed-use properties, and J.P. Morgan Global Alternatives announced today the acquisition of 615 Arsenal St. in Watertown, MA, a 126,460 sf, single-tenant Home Depot store, strategically located amidst Arsenal Yards, between 500 Forge and the rest of the retail, multi-family and life science components of the property.
Home Depot is a blue-chip, investment-grade-credit-rated retail tenant. Boylston Properties and institutional investors advised by J.P. Morgan Global Alternatives acquired the asset in the East End of Watertown, for $96.25M, under a joint venture agreement. Financed by Citizens Bank and Eastern Bank, the deal was brokered by Newmark on behalf of an affiliate of The Inland Real Estate Group of Companies, Inc.
“This is a logical investment that builds upon our commitment to lasting value creation at Arsenal Yards,” said Bill McQuillan, Founding Principal at Boylston Properties. “We look forward to deepening our relationship with Home Depot, and their long-term commitment to the East End of Watertown.”
Read the full press release
The Boston Globe: More life science companies are heading to Watertown
Five drug startups have signed leases to fill a building still under construction at the site of the old Arsenal Mall.
By Tim Logan, Globe Staff
In the latest sign that Watertown’s East End is becoming a magnet for life sciences companies, the first lab building to start construction there without any tenants will finish construction fully leased.
Boylston Properties, which is converting the old Arsenal Mall into a mixed-use complex known as Arsenal Yards, announced Wednesday that it has rented all of the space at 100 Forge — a nine-story, 165,600-square-foot building — to five venture capital-backed life science companies.
Read the full article from The Boston Globe
Boylston Properties Announces 100 Forge in Watertown is Now Fully Leased
Topping-off ceremony celebrated nine-story 165,595 sf building in the heart of Arsenal Yards, the future home to five life sciences companies
Watertown, MA – December 8, 2021 – Boylston Properties, a Boston-based developer of mixed-use destinations, today announced that 100 Forge, its 165,595 sf life sciences building in the heart of Arsenal Yards in Watertown, is fully leased. On November 9, the development, construction and new tenant teams celebrated with a “topping-off” ceremony – placing the last steel beam on the ninth floor of the future all-glass building. With access to abundant food, retail, entertainment, and green space amenities, as well as beautiful views of the Boston skyline and Charles River, 100 Forge will be the new home to five of the most innovative life sciences companies in the Greater Boston area.
With Arsenal Yards nearing the end of construction, life sciences companies are drawn to 100 Forge for its prime location within the 1M sf mixed-use campus, in order to recruit and retain the best talent to develop their science and further grow their companies. The following life sciences companies have signed leases, filling all of 100 Forge:
Read the full press release
- Abata Therapeutics – signing a 23,155-sf lease for floor 2 of 100 Forge, Abata is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases. Abata launched in 2021 with $95 million in Series A financing led by Third Rock Ventures and participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is moving to 100 Forge from Kendall Square in Cambridge.
- Remix Therapeutics – signing a 43,417-sf lease for floors 3 and 4 of 100 Forge, Remix is a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease. Remix, launched in 2019, has raised a total of $81M. The most recent Series A financing was led by Foresite Capital with participation from seed investors Atlas Venture and The Column Group, as well as Arch Venture, Casdin Capital and Alexandria Venture Investments. Remix is moving to 100 Forge from Kendall Square in Cambridge.
- Curie Therapeutics – signing a 39,661-sf lease for floors 5 and 6 of 100 Forge, Curie is building the leading, fully integrated oncology company harnessing novel precision radiopharmaceuticals to treat solid cancer. Curie is a series A stage company with a seasoned team of investors and founders including Atlas Venture, RA Capital Management, and Access Biotechnology.
- Vigil Neuroscience – signing a 19,734-sf lease for floor 7 of 100 Forge, Vigil is harnessing the power of microglia for the potential treatment of neurodegenerative diseases. Vigil recently closed a $90 million Series B financing led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as several new investors. Vigil is moving to 100 Forge from Kendall Square in Cambridge.
- Affini-T Therapeutics – signing a 39,628-sf lease for floors 8 and 9 of 100 Forge, Affini-T is a venture-backed biotechnology company committed to engineering T cell therapies intended to provide patients suffering from cancer with curative therapeutics. Affini-T is moving to 100 Forge from 343 Arsenal St. in Watertown.